Free Trial

Spartan Fund Management Inc. Makes New Investment in Cartesian Growth Co. II (NASDAQ:RENE)

Spartan Fund Management Inc. purchased a new stake in shares of Cartesian Growth Co. II (NASDAQ:RENE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 118,423 shares of the company's stock, valued at approximately $1,297,000. Cartesian Growth Co. II makes up about 1.6% of Spartan Fund Management Inc.'s investment portfolio, making the stock its 24th largest position. Spartan Fund Management Inc. owned 0.41% of Cartesian Growth Co. II at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wolverine Asset Management LLC grew its stake in Cartesian Growth Co. II by 29.2% in the 4th quarter. Wolverine Asset Management LLC now owns 464,171 shares of the company's stock valued at $5,078,000 after purchasing an additional 104,768 shares during the period. Wealthspring Capital LLC grew its position in Cartesian Growth Co. II by 0.3% during the fourth quarter. Wealthspring Capital LLC now owns 382,301 shares of the company's stock valued at $4,186,000 after buying an additional 1,305 shares during the period. Cowen AND Company LLC increased its holdings in Cartesian Growth Co. II by 2,758.2% during the third quarter. Cowen AND Company LLC now owns 562,526 shares of the company's stock worth $6,109,000 after buying an additional 542,845 shares during the last quarter. Westchester Capital Management LLC increased its holdings in Cartesian Growth Co. II by 2.4% during the third quarter. Westchester Capital Management LLC now owns 1,149,349 shares of the company's stock worth $12,413,000 after buying an additional 27,367 shares during the last quarter. Finally, Schechter Investment Advisors LLC raised its position in Cartesian Growth Co. II by 1,509.0% in the third quarter. Schechter Investment Advisors LLC now owns 1,381,322 shares of the company's stock worth $14,918,000 after acquiring an additional 1,295,471 shares during the period. 58.96% of the stock is currently owned by hedge funds and other institutional investors.


Cartesian Growth Co. II Price Performance

Shares of Cartesian Growth Co. II stock remained flat at $11.22 on Friday. 100,000 shares of the stock were exchanged, compared to its average volume of 41,273. The business has a 50 day moving average of $11.15 and a 200 day moving average of $11.03. Cartesian Growth Co. II has a 1 year low of $10.55 and a 1 year high of $11.92.

Cartesian Growth Co. II Company Profile

(Free Report)

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.

Read More

Institutional Ownership by Quarter for Cartesian Growth Co. II (NASDAQ:RENE)

→ Write this ticker symbol down… (From StocksToTrade) (Ad)

Should you invest $1,000 in Cartesian Growth Co. II right now?

Before you consider Cartesian Growth Co. II, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Growth Co. II wasn't on the list.

While Cartesian Growth Co. II currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Featured Articles and Offers

Biotech Boom: Stocks Skyrocketing & What's Next

Biotech Boom: Stocks Skyrocketing & What's Next

Dive into biotech's latest trends with Dylan Jovine: weight loss breakthroughs, smart chemo innovations, and expert stock evaluation tips.

Search Headlines: